This combined approach may also reduce intraoperative bleeding by decreasing tumor vascularity (28).Furthermore, previous studies have shown that denosumab inhibits osteoclast-like giant cells and modulates receptor tyrosine kinase signaling in GCTB, while sunitinib, a PDGFR inhibitor, significantly reduces the viability of tumor stromal cells by inhibiting PDGFR signaling, thereby increasing osteoprotegerin production in osteoblastic/stromal cells and attenuating RANKL/RANK signaling. Here, PDGFRB is linked to neoplasm.